Saturn V Capital Management

Latest statistics and disclosures from Saturn V Capital Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are ABVX, AMLX, COGT, JAZZ, PCVX, and represent 48.47% of Saturn V Capital Management's stock portfolio.
  • Added to shares of these 10 stocks: ALMS (+$31M), XFOR (+$23M), IVVD (+$19M), IMMX (+$16M), MNPR (+$11M), OCS (+$10M), IKT (+$7.9M), PHVS (+$7.0M), OCUL, OVID.
  • Started 8 new stock positions in XFOR, OCS, ALMS, IMMX, IVVD, IVA, IKT, OVID.
  • Reduced shares in these 10 stocks: COGT (-$29M), CGON (-$23M), ABVX (-$21M), XENE (-$20M), MRUS (-$17M), DYN (-$17M), LENZ (-$17M), CELC (-$16M), CNTA (-$11M), JAZZ (-$8.9M).
  • Sold out of its positions in CGON, LENZ, XENE, MRUS, NAMS.
  • Saturn V Capital Management was a net seller of stock by $-54M.
  • Saturn V Capital Management has $545M in assets under management (AUM), dropping by 19.50%.
  • Central Index Key (CIK): 0001964437

Tip: Access up to 7 years of quarterly data

Positions held by Saturn V Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Saturn V Capital Management

Saturn V Capital Management holds 20 positions in its portfolio as reported in the December 2025 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Abivax Sa Sponsored Ads (ABVX) 16.1 $88M -18% 649k 134.85
 View chart
Amylyx Pharmaceuticals (AMLX) 10.0 $54M -2% 4.5M 12.08
 View chart
Cogent Biosciences (COGT) 7.9 $43M -39% 1.2M 35.52
 View chart
Jazz Pharmaceuticals Shs Usd (JAZZ) 7.7 $42M -17% 248k 170.00
 View chart
Vaxcyte (PCVX) 6.8 $37M 799k 46.14
 View chart
Dyne Therapeutics (DYN) 6.4 $35M -33% 1.8M 19.56
 View chart
Pharvaris N V (PHVS) 5.8 $32M +28% 1.1M 27.75
 View chart
Celcuity (CELC) 5.8 $32M -33% 317k 99.74
 View chart
Alumis (ALMS) 5.6 $31M NEW 3.1M 9.76
 View chart
Disc Medicine (IRON) 4.3 $24M -12% 298k 79.41
 View chart
X4 Pharmaceuticals Com New (XFOR) 4.3 $23M NEW 5.8M 4.00
 View chart
Monopar Therapeutics Com New (MNPR) 3.9 $21M +109% 326k 65.30
 View chart
Adagio Therapeutics (IVVD) 3.5 $19M NEW 7.7M 2.47
 View chart
Ocular Therapeutix (OCUL) 3.4 $18M +30% 1.5M 12.14
 View chart
Immix Biopharma (IMMX) 2.9 $16M NEW 3.0M 5.23
 View chart
Oculis Holding Ordinary Shares (OCS) 1.9 $10M NEW 517k 19.97
 View chart
Inhibikase Therapeutics Com New (IKT) 1.5 $7.9M NEW 3.9M 2.05
 View chart
Centessa Pharmaceuticals Sponsored Ads (CNTA) 1.3 $7.1M -61% 283k 25.01
 View chart
Ovid Therapeutics (OVID) 0.7 $4.1M NEW 2.5M 1.63
 View chart
Inventiva Sa Ads (IVA) 0.2 $1.3M NEW 283k 4.65
 View chart

Past Filings by Saturn V Capital Management

SEC 13F filings are viewable for Saturn V Capital Management going back to 2022